PTC Therapeutics, Inc.

NasdaqGS:PTCT Stock Report

Market Cap: US$3.5b

PTC Therapeutics Past Earnings Performance

Past criteria checks 0/6

PTC Therapeutics's earnings have been declining at an average annual rate of -12.3%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 24.3% per year.

Key information

-12.3%

Earnings growth rate

-7.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate24.3%
Return on equityn/a
Net Margin-50.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth

Oct 09
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Sep 12

Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

Jun 28
Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

May 22

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

May 22
Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

May 14

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Mar 03
PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

Feb 11

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Jun 23
An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

May 18
Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Mar 02
An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Oct 19

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

Aug 05

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

Jul 20

Revenue & Expenses Breakdown

How PTC Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:PTCT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24901-4532930
30 Jun 24900-4803000
31 Mar 24928-5793190
31 Dec 23938-6273330
30 Sep 23798-6423490
30 Jun 23819-6183480
31 Mar 23770-5713400
31 Dec 22699-5593260
30 Sep 22697-5313200
30 Jun 22618-5563090
31 Mar 22569-5222980
31 Dec 21539-5242860
30 Sep 21492-4552740
30 Jun 21472-3912630
31 Mar 21430-4542470
31 Dec 20381-4382440
30 Sep 20358-4412330
30 Jun 20311-4322250
31 Mar 20322-2922200
31 Dec 19307-2522030
30 Sep 19297-2221880
30 Jun 19279-2131750
31 Mar 19262-1811590
31 Dec 18265-1281520
30 Sep 18256-781390
30 Jun 18245-611330
31 Mar 18224-691290
31 Dec 17194-791210
30 Sep 17142-1071080
30 Jun 17123-1081010
31 Mar 1790-130950
31 Dec 1683-142970
30 Sep 1670-166990
30 Jun 1657-174970
31 Mar 1648-174900
31 Dec 1537-170820
30 Sep 1537-147740
30 Jun 1529-131630
31 Mar 1524-118550
31 Dec 1425-94450
30 Sep 1417-84340
30 Jun 1432-62300
31 Mar 1437-51280
31 Dec 1335-66250

Quality Earnings: PTCT is currently unprofitable.

Growing Profit Margin: PTCT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PTCT is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare PTCT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: PTCT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies